Kester MI - Search Results

1

Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project.

Verhaar BJH, de Leeuw FA, Doorduijn AS, Fieldhouse JLP, van de Rest O, Teunissen CE, van Berckel BNM, Barkhof F, Visser M, de van der Schueren MAE, Scheltens P, Kester MI, Muller M, van der Flier WM. Verhaar BJH, et al. Among authors: kester mi. Alzheimers Dement (Amst). 2020 Aug 11;12(1):e12063. doi: 10.1002/dad2.12063. eCollection 2020. Alzheimers Dement (Amst). 2020. PMID: 32793798 Free PMC article.

2

CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.

Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der Flier WM. Kester MI, et al. J Alzheimers Dis. 2009;16(3):601-7. doi: 10.3233/JAD-2009-0999. J Alzheimers Dis. 2009. PMID: 19276554

3

Dementia: the bare essentials.

Kester MI, Scheltens P. Kester MI, et al. Pract Neurol. 2009 Aug;9(4):241-51. doi: 10.1136/jnnp.2009.182477. Pract Neurol. 2009. PMID: 19608778 Review. No abstract available.

4

Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.

Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM. Kester MI, et al. Neurobiol Aging. 2011 Aug;32(8):1372-8. doi: 10.1016/j.neurobiolaging.2009.08.006. Epub 2009 Sep 11. Neurobiol Aging. 2011. PMID: 19748159

5

Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition.

Goos JD, Kester MI, Barkhof F, Klein M, Blankenstein MA, Scheltens P, van der Flier WM. Goos JD, et al. Among authors: kester mi. Stroke. 2009 Nov;40(11):3455-60. doi: 10.1161/STROKEAHA.109.558197. Epub 2009 Sep 17. Stroke. 2009. PMID: 19762705

6

CSF biomarkers predict rate of cognitive decline in Alzheimer disease.

Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM. Kester MI, et al. Neurology. 2009 Oct 27;73(17):1353-8. doi: 10.1212/WNL.0b013e3181bd8271. Neurology. 2009. PMID: 19858456

7

Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects.

Verwey NA, Kester MI, van der Flier WM, Veerhuis R, Berkhof H, Twaalfhoven H, Blankenstein MA, Scheltens And P, Pijnenburg YA. Verwey NA, et al. Among authors: kester mi. J Alzheimers Dis. 2010;20(2):445-52. doi: 10.3233/JAD-2010-1392. J Alzheimers Dis. 2010. PMID: 20164558

8

Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease.

Kester MI, van der Flier WM, Mandic G, Blankenstein MA, Scheltens P, Muller M. Kester MI, et al. J Alzheimers Dis. 2010;20(4):1083-90. doi: 10.3233/JAD-2010-091198. J Alzheimers Dis. 2010. PMID: 20413898

9

Diagnostic impact of CSF biomarkers in a local hospital memory clinic.

Kester MI, Boelaarts L, Bouwman FH, Vogels RL, Groot ER, van Elk EJ, Blankenstein MA, van der Flier WM, Scheltens P. Kester MI, et al. Dement Geriatr Cogn Disord. 2010;29(6):491-7. doi: 10.1159/000313534. Epub 2010 Jun 3. Dement Geriatr Cogn Disord. 2010. PMID: 20523047

10

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop.

Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Teunissen CE, et al. Among authors: kester mi. Int J Alzheimers Dis. 2010 Sep 27;2010:635053. doi: 10.4061/2010/635053. Int J Alzheimers Dis. 2010. PMID: 20936143 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page